Resistance mechanisms to anti-PD cancer immunotherapy

MD Vesely, T Zhang, L Chen - Annual review of immunology, 2022 - annualreviews.org
The transformative success of antibodies targeting the PD-1 (programmed death 1)/B7-H1
(B7 homolog 1) pathway (anti-PD therapy) has revolutionized cancer treatment. However …
被引用次数：174 相关文章

Resistance Mechanisms to Anti-PD Cancer Immunotherapy

MD Vesely, T Zhang, L Chen - Annual review of …, 2022 - pubmed.ncbi.nlm.nih.gov
The transformative success of antibodies targeting the PD-1 (programmed death 1)/B7-H1
(B7 homolog 1) pathway (anti-PD therapy) has revolutionized cancer treatment. However …

Resistance Mechanisms to Anti-PD Cancer Immunotherapy.

MD Vesely, T Zhang, L Chen - Annual Review of Immunology, 2022 - europepmc.org
The transformative success of antibodies targeting the PD-1 (programmed death 1)/B7-H1
(B7 homolog 1) pathway (anti-PD therapy) has revolutionized cancer treatment. However …